In silico studies of blood coagulation proteins: from mosaic proteases to nonenzymatic cofactor inhibitors

Current Opinion in Structural Biology

Volumn 20, Issue 2, 2010, Pages 168-179

  Villoutreix, Bruno O ^a,b   Sperandio, Olivier ^a,b  

^a INSERM   (France)

^b CDithem Platform/IGM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 (5 AMIDINO 2 HYDROXYPHENYL) 1 [5 (2,6 DIMETHYL 1 PIPERIDINYL)PENTYL] 2(1H) QUINOXALINONE; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5A; OTAMIXABAN; PROTEINASE; RAZAXABAN; RIVAROXABAN; RPR 208815; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ANALYSIS; DISEASE PREDISPOSITION; DRUG SCREENING; DRUG STRUCTURE; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN POLYMORPHISM; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SEQUENCE HOMOLOGY; STRUCTURAL BIOINFORMATICS; THREE DIMENSIONAL IMAGING; THROMBOSIS;

ANIMALS; BLOOD COAGULATION FACTORS; COMPUTATIONAL BIOLOGY; FACTOR VA; FACTOR XA; HUMANS; MODELS, MOLECULAR; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEIN CONFORMATION;

EID: 77951290766     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2009.12.016     Document Type: Review

References (78)

1. Bick R.L. Introduction to thrombosis proficient and cost-effective approaches to thrombosis. Hematol Oncol Clin North Am 2003, 17:1-8. v.
2. Segers K., Dahlback B., Nicolaes G.A. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007, 98:530-542.
3. Sood S.L. Cancer-associated thrombosis. Curr Opin Hematol 2009, 16:378-385.
4. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008, 112:19-27.
5. Furie B., Furie B.C. Mechanisms of thrombus formation. N Engl J Med 2008, 359:938-949.
6. Dahlback B., Villoutreix B.O. The anticoagulant protein C pathway. FEBS Lett 2005, 579:3310-3316.
7. Dahlback B., Villoutreix B.O. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 2005, 25:1311-1320.
8. Villoutreix B.O. Structural bioinformatics: methods, concepts and applications to blood coagulation proteins. Curr Protein Pept Sci 2002, 3:341-364.
9. Cavasotto C.N., Phatak S.S. Homology modeling in drug discovery: current trends and applications. Drug Discov Today 2009, 14:676-683.
10. Zhang Y. Protein structure prediction: when is it useful?. Curr Opin Struct Biol 2009, 19:145-155.
11. Honig B., Nicholls A. Classical electrostatics in biology and chemistry. Science 1995, 268:1144-1149.
12. Goldsmith-Fischman S., Honig B. Structural genomics: computational methods for structure analysis. Protein Sci 2003, 12:1813-1821.
13. Wang H., Junghans C., Kremer K. Comparative atomistic and coarse-grained study of water: What do we lose by coarse-graining?. Eur Phys J E Soft Matter 2009, 28:221-229.
14. Mousseau N., Derreumaux P. Exploring energy landscapes of protein folding and aggregation. Front Biosci 2008, 13:4495-4516.
15. Karplus M., Kuriyan J. Molecular dynamics and protein function. Proc Natl Acad Sci U S A 2005, 102:6679-6685.
16. Laurie A.T., Jackson R.M. Methods for the prediction of protein-ligand binding sites for structure-based drug design and virtual ligand screening. Curr Protein Pept Sci 2006, 7:395-406.
17. Grosdidier S., Fernandez-Recio J. Identification of hot-spot residues in protein-protein interactions by computational docking. BMC Bioinformatics 2008, 9:447.
18. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
19. Villoutreix B.O., Bastard K., Sperandio O., Fahraeus R., Poyet J.L., Calvo F., Deprez B., Miteva M.A. In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr Pharm Biotechnol 2008, 9:103-122.
20. Bonvin A.M. Flexible protein-protein docking. Curr Opin Struct Biol 2006, 16:194-200.
21. Zhong S., Macias A.T., MacKerell A.D. Computational identification of inhibitors of protein-protein interactions. Curr Top Med Chem 2007, 7:63-82.
22. Andrusier N., Mashiach E., Nussinov R., Wolfson H.J. Principles of flexible protein-protein docking. Proteins 2008, 73:271-289.
23. Vakser I.A., Kundrotas P. Predicting 3D structures of protein-protein complexes. Curr Pharm Biotechnol 2008, 9:57-66.
24. Kortagere S., Krasowski M.D., Ekins S. The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci 2009, 30:138-147.
25. Vajda S., Kozakov D. Convergence and combination of methods in protein-protein docking. Curr Opin Struct Biol 2009, 19:164-170.
26. Totrov M., Abagyan R. Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 2008, 18:178-184.
27. Oprea T.I., Tropsha A., Faulon J.L., Rintoul M.D. Systems chemical biology. Nat Chem Biol 2007, 3:447-450.
28. Baskin I., Varnek A. Building a chemical space based on fragment descriptors. Comb Chem High Throughput Screen 2008, 11:661-668.
29. Sperandio O., Miteva M.A., Delfaud F., Villoutreix B.O. Receptor-based computational screening of compound databases: the main docking-scoring engines. Curr Protein Pept Sci 2006, 7:369-393.
30. Brown N., Jacoby E. On scaffolds and hopping in medicinal chemistry. Mini Rev Med Chem 2006, 6:1217-1229.
31. Engel T. Basic overview of chemoinformatics. J Chem Inf Model 2006, 46:2267-2277.
32. Di L., Kerns E.H., Carter G.T. Drug-like property concepts in pharmaceutical design. Curr Pharm Des 2009, 15:2184-2194.
33. Valerio L.G. In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol 2009, 241:356-370.
34. Hansson K., Stenflo J. Post-translational modifications in proteins involved in blood coagulation. J Thromb Haemost 2005, 3:2633-2648.
35. Perera L., Darden T.A., Pedersen L.G. Predicted solution structure of zymogen human coagulation FVII. J Comput Chem 2002, 23:35-47.
36. Perera L., Foley C., Darden T.A., Stafford D., Mather T., Esmon C.T., Pedersen L.G. Modeling zymogen protein C. Biophys J 2000, 79:2925-2943.
37. Venkateswarlu D., Perera L., Darden T., Pedersen L.G. Structure and dynamics of zymogen human blood coagulation factor X. Biophys J 2002, 82:1190-1206.
38. Villoutreix B.O., Covell D.G., Blom A.M., Wallqvist A., Friedrich U., Dahlback B. Screening the molecular surface of human anticoagulant protein C: a search for interaction sites. J Comput Aid Mol Des 2001, 15:13-27.
39. Friedrich U., Blom A.M., Dahlback B., Villoutreix B.O. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 2001, 276:24122-24128.
40. Perera L., Darden T.A., Pedersen L.G. Modeling human zymogen factor IX. Thromb Haemost 2001, 85:596-603.
41. Fuentes-Prior P., Fujikawa K., Pratt K.P. New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr Protein Pept Sci 2002, 3:313-339.
42. Orban T., Kalafatis M., Gogonea V. Completed three-dimensional model of human coagulation factor Va. Molecular dynamics simulations and structural analyses. Biochemistry 2005, 44:13082-13090.
43. Autin L., Miteva M.A., Lee W.H., Mertens K., Radtke K.P., Villoutreix B.O. Molecular models of the procoagulant factor VIIIa-factor IXa complex. J Thromb Haemost 2005, 3:2044-2056.
44. Autin L., Steen M., Dahlback B., Villoutreix B.O. Proposed structural models of the prothrombinase (FXa-FVa) complex. Proteins 2006, 63:440-450.
45. Lee C.J., Lin P., Chandrasekaran V., Duke R.E., Everse S.J., Perera L., Pedersen L.G. Proposed structural models of human factor Va and prothrombinase. J Thromb Haemost 2008, 6:83-89.
46. Ngo J.C., Huang M., Roth D.A., Furie B.C., Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008, 16:597-606.
47. Shen B.W., Spiegel P.C., Chang C.H., Huh J.W., Lee J.S., Kim J., Kim Y.H., Stoddard B.L. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008, 111:1240-1247.
48. Stoilova-McPhie S., Parmenter C.D., Segers K., Villoutreix B.O., Nicolaes G.A. Defining the structure of membrane-bound human blood coagulation factor Va. J Thromb Haemost 2008, 6:76-82.
49. Mollica L., Fraternali F., Musco G. Interactions of the C2 domain of human factor V with a model membrane. Proteins 2006, 64:363-375.
50. Olsen O.H., Rand K.D., Ostergaard H., Persson E. A combined structural dynamics approach identifies a putative switch in factor VIIa employed by tissue factor to initiate blood coagulation. Protein Sci 2007, 16:671-682.
51. Fernandez-Busquets X., de Groot N.S., Fernandez D., Ventura S. Recent structural and computational insights into conformational diseases. Curr Med Chem 2008, 15:1336-1349.
52. Gooptu B., Lomas D.A. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem 2009, 78:147-176.
53. Rochet J.C. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med 2007, 9:1-34.
54. Carrell R.W., Stein P.E. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol Chem Hoppe Seyler 1996, 377:1-17.
55. Delev D., Pavlova A., Heinz S., Blaise M.C., Chandra T., Poetsch B., Seifried E., Oldenburg J. Modelling and expression studies of two novel mutations causing factor V deficiency. Thromb Haemost 2008, 100:766-772.
56. Nair D.G., Sunilkumar P.N., Sadasivan C. Modeling of factor XIII activation peptide (28-41) V34L mutant bound to thrombin. J Biomol Struct Dyn 2008, 26:387-394.
57. Grosdidier S., Totrov M., Fernandez-Recio J. Computer applications to prediction of protein-protein interactions and rational drug design. Adv Appl Bioinform Chem 2009, 2:101-123.
58. Steen M., Tran S., Autin L., Villoutreix B.O., Tholander A.L., Dahlback B. Mapping of the factor Xa binding site on factor Va by site-directed mutagenesis. J Biol Chem 2008, 283:20805-20812.
59. Prezelj A., Anderluh P.S., Peternel L., Urleb U. Recent advances in serine protease inhibitors as anticoagulant agents. Curr Pharm Des 2007, 13:287-312.
60. Weitz J.I., Linkins L.A. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin Investig Drugs 2007, 16:271-282.
61. Crowther M.A., Warkentin T.E. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost 2009, 7(Suppl 1):107-110.
62. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006, 5:785-799.
63. Garcia D. Novel anticoagulants and the future of anticoagulation. Thromb Res 2009, 123(Suppl 4):S50-S55.
64. Henry B.L., Desai U.R. Recent research developments in the direct inhibition of coagulation proteinases-inhibitors of the initiation phase. Cardiovasc Hematol Agents Med Chem 2008, 6:323-336.
65. Lehar J., Stockwell B.R., Giaever G., Nislow C. Combination chemical genetics. Nat Chem Biol 2008, 4:674-681.
66. Turpie A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007, 27:1238-1247.
67. Rauh D., Klebe G., Stubbs M.T. Understanding protein-ligand interactions: the price of protein flexibility. J Mol Biol 2004, 335:1325-1341.
68. Lam P.Y., Clark C.G., Li R., Pinto D.J., Orwat M.J., Galemmo R.A., Fevig J.M., Teleha C.A., Alexander R.S., Smallwood A.M., et al. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J Med Chem 2003, 46:4405-4418.
69. Pinto D.J., Orwat M.J., Koch S., Rossi K.A., Alexander R.S., Smallwood A., Wong P.C., Rendina A.R., Luettgen J.M., Knabb R.M., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007, 50:5339-5356.
70. Quan M.L., Lam P.Y., Han Q., Pinto D.J., He M.Y., Li R., Ellis C.D., Clark C.G., Teleha C.A., Sun J.H., et al. Discovery of 1-(3′-aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 2005, 48:1729-1744.
71. Roehrig S., Straub A., Pohlmann J., Lampe T., Pernerstorfer J., Schlemmer K.H., Reinemer P., Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005, 48:5900-5908.
72. Krovat E.M., Fruhwirth K.H., Langer T. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa. J Chem Inf Model 2005, 45:146-159.
73. Fontaine F., Pastor M., Zamora I., Sanz F. Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors. J Med Chem 2005, 48:2687-2694.
74. Lin H.H., Han L.Y., Yap C.W., Xue Y., Liu X.H., Zhu F., Chen Y.Z. Prediction of factor Xa inhibitors by machine learning methods. J Mol Graph Model 2007, 26:505-518.
75. Van Huis C.A., Bigge C.F., Casimiro-Garcia A., Cody W.L., Dudley D.A., Filipski K.J., Heemstra R.J., Kohrt J.T., Narasimhan L.S., Schaum R.P., et al. Structure-based drug design of pyrrolidine-1,2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors. Chem Biol Drug Des 2007, 69:444-450.
76. Murcia M., Ortiz A.R. Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. J Med Chem 2004, 47:805-820.
77. Matter H., Will D.W., Nazare M., Schreuder H., Laux V., Wehner V. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. J Med Chem 2005, 48:3290-3312.
78. Segers K., Sperandio O., Sack M., Fischer R., Miteva M.A., Rosing J., Nicolaes G.A., Villoutreix B.O. Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V. Proc Natl Acad Sci U S A 2007, 104:12697-12702.